AusCann Group Holdings Ltd
AusCann Group Holdings Ltd (AC8.AX) Stock Competitors & Peer Comparison
See (AC8.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AC8.AX | A$0.04 | +0.00% | 17.6M | -0.67 | -A$0.06 | N/A |
| AFP.AX | A$3.03 | -0.66% | 319.8M | 23.46 | A$0.13 | +0.55% |
| CAU.AX | A$0.54 | +0.00% | 300.5M | -16.88 | -A$0.03 | N/A |
| PBP.AX | A$2.98 | -0.33% | 242.3M | 29.80 | A$0.10 | +3.61% |
| LV1.AX | A$0.92 | +0.00% | 144.1M | 3.05 | A$0.30 | N/A |
| VLS.AX | A$2.56 | +0.00% | 136.1M | 14.22 | A$0.18 | +5.47% |
| ANP.AX | A$0.06 | -4.92% | 52.3M | -2.90 | -A$0.02 | N/A |
| MVP.AX | A$0.40 | +0.00% | 46.2M | -1.21 | -A$0.34 | N/A |
| NXS.AX | A$0.15 | +0.00% | 42.4M | -2.90 | -A$0.05 | +100.00% |
| SNT.AX | A$0.03 | +0.00% | 39M | -2.60 | -A$0.01 | N/A |
Stock Comparison
AC8.AX vs AFP.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, AFP.AX has a market cap of 319.8M. Regarding current trading prices, AC8.AX is priced at A$0.04, while AFP.AX trades at A$3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas AFP.AX's P/E ratio is 23.46. In terms of profitability, AC8.AX's ROE is -0.61%, compared to AFP.AX's ROE of +0.18%. Regarding short-term risk, AC8.AX is less volatile compared to AFP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check AFP.AX's competition here
AC8.AX vs CAU.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, CAU.AX has a market cap of 300.5M. Regarding current trading prices, AC8.AX is priced at A$0.04, while CAU.AX trades at A$0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas CAU.AX's P/E ratio is -16.88. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CAU.AX's ROE of +0.34%. Regarding short-term risk, AC8.AX is less volatile compared to CAU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check CAU.AX's competition here
AC8.AX vs PBP.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, PBP.AX has a market cap of 242.3M. Regarding current trading prices, AC8.AX is priced at A$0.04, while PBP.AX trades at A$2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas PBP.AX's P/E ratio is 29.80. In terms of profitability, AC8.AX's ROE is -0.61%, compared to PBP.AX's ROE of +0.13%. Regarding short-term risk, AC8.AX is more volatile compared to PBP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check PBP.AX's competition here
AC8.AX vs LV1.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, LV1.AX has a market cap of 144.1M. Regarding current trading prices, AC8.AX is priced at A$0.04, while LV1.AX trades at A$0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas LV1.AX's P/E ratio is 3.05. In terms of profitability, AC8.AX's ROE is -0.61%, compared to LV1.AX's ROE of -7.25%. Regarding short-term risk, AC8.AX is more volatile compared to LV1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check LV1.AX's competition here
AC8.AX vs VLS.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, VLS.AX has a market cap of 136.1M. Regarding current trading prices, AC8.AX is priced at A$0.04, while VLS.AX trades at A$2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas VLS.AX's P/E ratio is 14.22. In terms of profitability, AC8.AX's ROE is -0.61%, compared to VLS.AX's ROE of +0.19%. Regarding short-term risk, AC8.AX is more volatile compared to VLS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check VLS.AX's competition here
AC8.AX vs ANP.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, ANP.AX has a market cap of 52.3M. Regarding current trading prices, AC8.AX is priced at A$0.04, while ANP.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas ANP.AX's P/E ratio is -2.90. In terms of profitability, AC8.AX's ROE is -0.61%, compared to ANP.AX's ROE of -0.73%. Regarding short-term risk, AC8.AX is less volatile compared to ANP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check ANP.AX's competition here
AC8.AX vs MVP.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, MVP.AX has a market cap of 46.2M. Regarding current trading prices, AC8.AX is priced at A$0.04, while MVP.AX trades at A$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas MVP.AX's P/E ratio is -1.21. In terms of profitability, AC8.AX's ROE is -0.61%, compared to MVP.AX's ROE of -0.01%. Regarding short-term risk, AC8.AX is more volatile compared to MVP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check MVP.AX's competition here
AC8.AX vs NXS.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, NXS.AX has a market cap of 42.4M. Regarding current trading prices, AC8.AX is priced at A$0.04, while NXS.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas NXS.AX's P/E ratio is -2.90. In terms of profitability, AC8.AX's ROE is -0.61%, compared to NXS.AX's ROE of -4.91%. Regarding short-term risk, AC8.AX is more volatile compared to NXS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check NXS.AX's competition here
AC8.AX vs SNT.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, SNT.AX has a market cap of 39M. Regarding current trading prices, AC8.AX is priced at A$0.04, while SNT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas SNT.AX's P/E ratio is -2.60. In terms of profitability, AC8.AX's ROE is -0.61%, compared to SNT.AX's ROE of -0.62%. Regarding short-term risk, AC8.AX is more volatile compared to SNT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check SNT.AX's competition here
AC8.AX vs LGP.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, LGP.AX has a market cap of 29.1M. Regarding current trading prices, AC8.AX is priced at A$0.04, while LGP.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas LGP.AX's P/E ratio is 4.75. In terms of profitability, AC8.AX's ROE is -0.61%, compared to LGP.AX's ROE of +0.10%. Regarding short-term risk, AC8.AX is more volatile compared to LGP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check LGP.AX's competition here
AC8.AX vs VIT.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, VIT.AX has a market cap of 23.2M. Regarding current trading prices, AC8.AX is priced at A$0.04, while VIT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas VIT.AX's P/E ratio is 3.50. In terms of profitability, AC8.AX's ROE is -0.61%, compared to VIT.AX's ROE of +0.02%. Regarding short-term risk, AC8.AX is more volatile compared to VIT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check VIT.AX's competition here
AC8.AX vs CPH.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, CPH.AX has a market cap of 23.1M. Regarding current trading prices, AC8.AX is priced at A$0.04, while CPH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas CPH.AX's P/E ratio is -0.45. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CPH.AX's ROE of -1.31%. Regarding short-term risk, AC8.AX is more volatile compared to CPH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check CPH.AX's competition here
AC8.AX vs PXS.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, PXS.AX has a market cap of 20.2M. Regarding current trading prices, AC8.AX is priced at A$0.04, while PXS.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas PXS.AX's P/E ratio is -1.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to PXS.AX's ROE of -1.12%. Regarding short-term risk, AC8.AX is more volatile compared to PXS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check PXS.AX's competition here
AC8.AX vs MXC.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, MXC.AX has a market cap of 18.4M. Regarding current trading prices, AC8.AX is priced at A$0.04, while MXC.AX trades at A$0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas MXC.AX's P/E ratio is -0.13. In terms of profitability, AC8.AX's ROE is -0.61%, compared to MXC.AX's ROE of +26.60%. Regarding short-term risk, AC8.AX is less volatile compared to MXC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check MXC.AX's competition here
AC8.AX vs AGH.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, AGH.AX has a market cap of 16.9M. Regarding current trading prices, AC8.AX is priced at A$0.04, while AGH.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas AGH.AX's P/E ratio is -2.00. In terms of profitability, AC8.AX's ROE is -0.61%, compared to AGH.AX's ROE of +43.88%. Regarding short-term risk, AC8.AX is less volatile compared to AGH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check AGH.AX's competition here
AC8.AX vs PKP.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, PKP.AX has a market cap of 16M. Regarding current trading prices, AC8.AX is priced at A$0.04, while PKP.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas PKP.AX's P/E ratio is -1.60. In terms of profitability, AC8.AX's ROE is -0.61%, compared to PKP.AX's ROE of N/A. Regarding short-term risk, AC8.AX is less volatile compared to PKP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check PKP.AX's competition here
AC8.AX vs IDT.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, IDT.AX has a market cap of 14.5M. Regarding current trading prices, AC8.AX is priced at A$0.04, while IDT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas IDT.AX's P/E ratio is -3.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to IDT.AX's ROE of -0.29%. Regarding short-term risk, AC8.AX is more volatile compared to IDT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check IDT.AX's competition here
AC8.AX vs IHL.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, IHL.AX has a market cap of 14.3M. Regarding current trading prices, AC8.AX is priced at A$0.04, while IHL.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas IHL.AX's P/E ratio is -0.03. In terms of profitability, AC8.AX's ROE is -0.61%, compared to IHL.AX's ROE of -0.33%. Regarding short-term risk, AC8.AX is less volatile compared to IHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check IHL.AX's competition here
AC8.AX vs HGV.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, HGV.AX has a market cap of 10.1M. Regarding current trading prices, AC8.AX is priced at A$0.04, while HGV.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas HGV.AX's P/E ratio is -2.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to HGV.AX's ROE of -0.01%. Regarding short-term risk, AC8.AX is more volatile compared to HGV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check HGV.AX's competition here
AC8.AX vs EPN.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, EPN.AX has a market cap of 8.9M. Regarding current trading prices, AC8.AX is priced at A$0.04, while EPN.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas EPN.AX's P/E ratio is -2.30. In terms of profitability, AC8.AX's ROE is -0.61%, compared to EPN.AX's ROE of +4.05%. Regarding short-term risk, AC8.AX is less volatile compared to EPN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check EPN.AX's competition here
AC8.AX vs EOF.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, EOF.AX has a market cap of 7.3M. Regarding current trading prices, AC8.AX is priced at A$0.04, while EOF.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas EOF.AX's P/E ratio is -0.50. In terms of profitability, AC8.AX's ROE is -0.61%, compared to EOF.AX's ROE of -0.77%. Regarding short-term risk, AC8.AX is less volatile compared to EOF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check EOF.AX's competition here
AC8.AX vs ECS.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, ECS.AX has a market cap of 6.5M. Regarding current trading prices, AC8.AX is priced at A$0.04, while ECS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas ECS.AX's P/E ratio is N/A. In terms of profitability, AC8.AX's ROE is -0.61%, compared to ECS.AX's ROE of -0.20%. Regarding short-term risk, AC8.AX is less volatile compared to ECS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check ECS.AX's competition here
AC8.AX vs CGB.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, CGB.AX has a market cap of 5.6M. Regarding current trading prices, AC8.AX is priced at A$0.04, while CGB.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas CGB.AX's P/E ratio is -0.70. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CGB.AX's ROE of -0.61%. Regarding short-term risk, AC8.AX is more volatile compared to CGB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check CGB.AX's competition here
AC8.AX vs IVX.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, IVX.AX has a market cap of 4.8M. Regarding current trading prices, AC8.AX is priced at A$0.04, while IVX.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas IVX.AX's P/E ratio is -0.35. In terms of profitability, AC8.AX's ROE is -0.61%, compared to IVX.AX's ROE of -1.50%. Regarding short-term risk, AC8.AX is more volatile compared to IVX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check IVX.AX's competition here
AC8.AX vs PER.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, PER.AX has a market cap of 4.5M. Regarding current trading prices, AC8.AX is priced at A$0.04, while PER.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas PER.AX's P/E ratio is -0.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to PER.AX's ROE of -1.11%. Regarding short-term risk, AC8.AX is less volatile compared to PER.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check PER.AX's competition here
AC8.AX vs BOD.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, BOD.AX has a market cap of 4.3M. Regarding current trading prices, AC8.AX is priced at A$0.04, while BOD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas BOD.AX's P/E ratio is -0.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to BOD.AX's ROE of -0.05%. Regarding short-term risk, AC8.AX is less volatile compared to BOD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check BOD.AX's competition here
AC8.AX vs SCU.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, SCU.AX has a market cap of 3.9M. Regarding current trading prices, AC8.AX is priced at A$0.04, while SCU.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas SCU.AX's P/E ratio is N/A. In terms of profitability, AC8.AX's ROE is -0.61%, compared to SCU.AX's ROE of -0.82%. Regarding short-term risk, AC8.AX is less volatile compared to SCU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check SCU.AX's competition here
AC8.AX vs CAN.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, CAN.AX has a market cap of 3.5M. Regarding current trading prices, AC8.AX is priced at A$0.04, while CAN.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas CAN.AX's P/E ratio is 0.50. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CAN.AX's ROE of +0.94%. Regarding short-term risk, AC8.AX is more volatile compared to CAN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check CAN.AX's competition here
AC8.AX vs RGT.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, RGT.AX has a market cap of 3.2M. Regarding current trading prices, AC8.AX is priced at A$0.04, while RGT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas RGT.AX's P/E ratio is -0.35. In terms of profitability, AC8.AX's ROE is -0.61%, compared to RGT.AX's ROE of +2.59%. Regarding short-term risk, AC8.AX is more volatile compared to RGT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check RGT.AX's competition here
AC8.AX vs BP8.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, BP8.AX has a market cap of 2.8M. Regarding current trading prices, AC8.AX is priced at A$0.04, while BP8.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas BP8.AX's P/E ratio is N/A. In terms of profitability, AC8.AX's ROE is -0.61%, compared to BP8.AX's ROE of +0.95%. Regarding short-term risk, AC8.AX is more volatile compared to BP8.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check BP8.AX's competition here
AC8.AX vs EXL.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, EXL.AX has a market cap of 1.5M. Regarding current trading prices, AC8.AX is priced at A$0.04, while EXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas EXL.AX's P/E ratio is -0.35. In terms of profitability, AC8.AX's ROE is -0.61%, compared to EXL.AX's ROE of -0.76%. Regarding short-term risk, AC8.AX is less volatile compared to EXL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.Check EXL.AX's competition here
AC8.AX vs TSN.AX Comparison May 2026
AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AC8.AX stands at 17.6M. In comparison, TSN.AX has a market cap of 1.4M. Regarding current trading prices, AC8.AX is priced at A$0.04, while TSN.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AC8.AX currently has a P/E ratio of -0.67, whereas TSN.AX's P/E ratio is -0.33. In terms of profitability, AC8.AX's ROE is -0.61%, compared to TSN.AX's ROE of -0.97%. Regarding short-term risk, AC8.AX is more volatile compared to TSN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.Check TSN.AX's competition here